Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:** 2',3'-Dideoxythymidine‑5'‑monophosphate (ddTMP) is a synthetic pyrimidine nucleotide analog in which the ribose moiety lacks hydroxyl groups at both the 2' and 3' positions. It is structurally related to thymidine monophosphate but differs by these missing hydroxyls. This modification prevents further chain elongation when incorporated into DNA or RNA by polymerases. **Mechanism of Action:** ddTMP acts as a chain terminator during nucleic acid synthesis because its incorporation into DNA or RNA precludes the addition of subsequent nucleotides due to the absence of critical hydroxyl groups required for phosphodiester bond formation. It has been studied primarily as an investigative tool and potential antiviral agent targeting viral polymerases and kinases such as Mycobacterium thymidine monophosphate kinase[8]. Its main use is experimental; it is not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2',3'-dideoxythymidine-5'-monophosphate.